CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients.
BACKGROUND
Noninvasive tests measuring cellular immunity could help predict immunologic risk and subsequent allograft dysfunction in transplant patients. CD25 is a promising marker of activation. Recent descriptions of CD127 expression as a discriminating factor between regulatory and activated T cells suggest its potential utility.


METHODS
Expression of CD127 in CD4+CD25 T cells was analyzed by flow cytometry in peripheral blood from 62 renal transplanted patients and 30 healthy controls. Forty patients presented stable graft function and 22 suffered renal failure.


RESULTS
Renal transplant patients showed higher levels of CD127(high) and a lower frequency of CD127(low) than healthy controls (0.63% vs. 0.29% [P<0.001] and 1.4% vs. 2.4% [P<0.001], respectively). However, high frequencies of not only CD127(high) but also CD127(low) showed a significant correlation with serum creatinine levels (P=0.012 and P=0.003, respectively). Allogenic stimulation in vitro increased the frequency of CD127(low) subset in a dose dependent manner. Furthermore, in patients with a high frequency of CD127(low) subset, this consisted mostly of FoxP3 negative cells, discarding their regulatory origin. Median frequency of CD127(low), but not CD127(high), cells showed significant differences between patients with stable function and with renal failure (P<0.005), with 16.7% and 53.1% of individuals above the median CD127(low) value (1.4%), respectively.


CONCLUSIONS
Quantification of CD127(low) subset through staining of CD4+ T cells with the combined markers CD127/CD25/CD45RO has been demonstrated to be a significant tool for monitoring the outcome course of renal transplant patients.
Alonso-Arias
Rebeca
R
Histocompatibility Unit, Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Suárez-Alvarez
Beatriz
B
López-Vázquez
Antonio
A
Moro
Marco A
MA
Baltar
José
J
Gómez-Huertas
Ernesto
E
Ortega
Teresa
T
Ortega
Francisco
F
López-Larrea
Carlos
C
D015703:Antigens, CD / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis* / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D051858:Forkhead Transcription Factors / Q000032:analysis / Q000172:deficiency; D005786:Gene Expression Regulation / Q000276:immunology; D006084:Graft Rejection / Q000175:diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053699:Interleukin-7 Receptor alpha Subunit / Q000235:genetics*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012016:Reference Values; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
D015703:Antigens, CD; D015415:Biomarkers; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D007166:Immunosuppressive Agents; D053699:Interleukin-7 Receptor alpha Subunit; D003404:Creatinine; D009173:Mycophenolic Acid; D016559:Tacrolimus